Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
31.61
Nov 05 • 3:59 PM ET Dollar change-0.72 Percentage change(-2.23%)
Aftermarket Close
31.61
Aftermarket • 5:00 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
290.43M
Enterprise Value
323.53M
Income
-32.01M
Sales
109.81M
Book/sh
0.86
Cash/sh
1.68
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
108
IPO
Apr 07, 1994
P/E
-
Forward P/E
54.03
PEG
-
P/S
2.64
P/B
36.58
P/C
18.83
P/FCF
64.54
EV/EBITDA
23.31
EV/Sales
2.95
Quick Ratio
2.30
Current Ratio
2.58
Debt/Eq
6.11
LT Debt/Eq
6.06
Option/Short
No / Yes
EPS (ttm)
-3.71
EPS next Y
0.58
EPS next Q
0.06
EPS this Y
480.00%
EPS next Y
207.89%
EPS next 5Y
-
EPS past 3/5Y
-63.11% -41.80%
Sales past 3/5Y
31.03% 45.92%
EPS Y/Y TTM
-219.19%
Sales Y/Y TTM
12.93%
EPS Q/Q
77.64%
Sales Q/Q
8.93%
Insider Own
46.90%
Insider Trans
0.00%
Inst Own
19.78%
Inst Trans
-0.76%
ROA
-0.34%
ROE
-1.31%
ROIC
-57.08%
Gross Margin
90.77%
Oper. Margin
10.38%
Profit Margin
-29.15%
SMA20
-5.09%
SMA50
-7.86%
SMA200
23.15%
Trades
Shs Outstand
9.19M
Shs Float
4.88M
52W High
35.52 -11.01%
52W Low
16.05 96.99%
Volatility
4.60% 2.73%
ATR (14)
0.89
RSI (14)
21.30
Beta
1.20
Rel Volume
0.37
Avg Volume
225.83K
Volume
83,287
Perf Week
-3.96%
Perf Month
-9.81%
Perf Quarter
-7.30%
Perf Half Y
65.67%
Perf YTD
35.37%
Perf Year
14.53%
Perf 3Y
17.12%
Perf 5Y
-16.10%
Perf 10Y
533.47%
Prev Close
32.33
Price
31.61
Change %
-2.23%
Consensus
Hold
Avg. Price Target
$35.00
Implied Upside
+10.7%
Analysts3incl. previous ratings
Rating Distribution2 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 30, 2026Downgrade
HH.C. Wainwright
Buy → Neutral$35+10.7%
Apr 15, 2026Initiated
LLake Street
Buy$32+1.2%
Mar 26, 2025Reiterated
HH.C. Wainwright
Buy$50 → $51+61.3%
Dec 23, 2024Initiated
HH.C. Wainwright
Buy$50+58.2%
May 20, 2022Resumed
CCantor Fitzgerald
Overweight$45 → $40+26.5%
Jun 30, 2021Initiated
CCantor Fitzgerald
Overweight$45+42.4%
Sanara MedTech, Inc. engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.
Executive ChairmanMr. Ronald T. Nixon
PresidentMr. Seth D. Yon
Chief Financial OfficerMs. Elizabeth B. Taylor
Chief Operating OfficerMr. Jacob A. Waldrop
Principal Accounting OfficerMs. Ashley M. Mackey